Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Lexeo Therapeutics logo — Advancing science with curative potential for both cardiovas...

Lexeo Therapeutics

Advancing science with curative potential for both cardiovascular and APOE4 associated Alzheimer's disease areas.

Founded 2018 United States New York, United States 97 employees Post-IPO Equity Total: $280.00M Biotechnology, Health and Wellness +1

General Information

Company Name Lexeo Therapeutics
Founded Year 2018
Location United States New York, United States
Founders / Decision Makers
Team member Team member Team member Team member
Employees 97
Industries Biotechnology, Health and Wellness, Life Sciences
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Lexeo Therapeutics. To contact Lexeo Therapeutics, visit lexeotx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Lexeo Therapeutics compare?

A PDF of Lexeo Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Lexeo Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Lexeo Therapeutics

Lexeo Therapeutics is a New York City-based biotechnology startup that is making waves in the field of genetic medicines. The company is on a mission to revolutionize healthcare by leveraging cutting-edge science to change the way diseases are treated. Its focus areas include cardiovascular and APOE4 associated Alzheimer's disease. By collaborating with leading institutions such as Weill Cornell Medicine and the University of California San Diego, Lexeo Therapeutics has been able to advance its pipeline through a stepwise development approach, utilizing early proof-of-concept functional and biomarker data. The startup, established in 2018, has garnered significant attention from investors and recently secured a substantial $95.00M Post-IPO Equity investment on 11 March 2024. This round of funding was backed by prominent investors including Novo Holdings, RA Capital Management, Adage Capital Management, Braidwell, Eventide Asset Management, and Surveyor Capital, further solidifying Lexeo Therapeutics' position in the industry. With a team of experts boasting extensive experience in genetic medicines, rare disease drug development, manufacturing, and commercialization, Lexeo Therapeutics is well-positioned to drive innovations in the biotechnology sector and potentially bring curative treatments to patients in need. For more information, you can visit their website at www.lexeotx.com.

Business keywords: genetic medicine, clinical-stage, gene therapy, rare diseases, cardiovascular diseases, Alzheimer's disease, AAV-mediated therapies, Weill Cornell Medicine, University of California San Diego, New York City, research collaboration, commercialization, preclinical pipeline, innovation

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $95.00M 6
Novo Holdings RA Capital Management Adage Capital Management
Novo Holdings, RA Capital Management +4
11 Mar 2024
Corporate Round Undisclosed 1
Sarepta Therapeutics
28 Aug 2023
Series B $100.00M 3
Janus Handerson Omega Funds
Janus Handerson, Omega Funds +1
09 Sep 2021
Series A $85.00M -
07 Jan 2021

Latest News

View All
FDA reversals leave investors worrying about the fates of other experimental drugs — Cnbc
FDA reversals leave investors worrying about the fates of other experimental drugs
Cnbc Mar 06, 2026

Lexeo Therapeutics Alternatives & Competitors

View All Alternatives
Lexeo Therapeutics vs
Renovacor
Renovacor

Advancing transformative therapies for cardiovascular disease

Post-IPO Equity
6 employees
Biotechnology, Health Care
Compare Lexeo Therapeutics vs Renovacor
Lexeo Therapeutics vs
Taysha Gene Therapies
Taysha Gene Therapies United States

Taysha Gene Therapies is focused on advancing AAV-based gene therapies for severe monogenic diseases...

IPO
134 employees
Biotechnology, Life Sciences
Compare Lexeo Therapeutics vs Taysha Gene Therapies
Lexeo Therapeutics vs
Passage Bio
Passage Bio United States

Our mission is to improve the lives of patients with neurodegenerative diseases

Post-IPO Equity
43 employees
Biotechnology, Health Care
Compare Lexeo Therapeutics vs Passage Bio
Also compare with: Lexeo Therapeutics vs Locanabio, Inc. Locanabio, Inc. View all alternatives

FAQ About Lexeo Therapeutics

Advancing science with curative potential for both cardiovascular and APOE4 associated Alzheimer's disease areas.
Lexeo Therapeutics was founded in 2018.
Lexeo Therapeutics is headquartered in New York, United States.
Lexeo Therapeutics operates in Biotechnology, Health and Wellness and Life Sciences. Its work centres on genetic medicine, clinical-stage, gene therapy and rare diseases.
Lexeo Therapeutics has approximately 97 employees.
Lexeo Therapeutics has completed 4 funding rounds, raising a total of $280.00M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Lexeo Therapeutics include Renovacor, Taysha Gene Therapies, Passage Bio, Raptor Pharmaceuticals, Locanabio, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Lexeo Therapeutics and Renovacor are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Lexeo Therapeutics, https://bouncewatch.com/company/lexeo-therapeutics, updated 4 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout